Bioventus Inc. (BVS)
NASDAQ: BVS · IEX Real-Time Price · USD
3.960
-0.110 (-2.70%)
Apr 30, 2024, 4:00 PM EDT - Market closed
Bioventus Revenue
In the year 2023, Bioventus had annual revenue of $512.35M with 0.04% growth. Revenue in the quarter ending December 31, 2023 was $135.42M with 7.62% year-over-year growth.
Revenue (ttm)
$512.35M
Revenue Growth
+0.04%
P/S Ratio
0.49
Revenue / Employee
$528,191
Employees
970
Market Cap
250.98M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 512.35M | 228.00K | 0.04% |
| Dec 31, 2022 | 512.12M | 81.22M | 18.85% |
| Dec 31, 2021 | 430.90M | 109.74M | 34.17% |
| Dec 31, 2020 | 321.16M | -18.98M | -5.58% |
| Dec 31, 2019 | 340.14M | 20.96M | 6.57% |
| Dec 31, 2018 | 319.18M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 23andMe Holding Co. | 247.99M |
| Xeris Biopharma Holdings | 163.91M |
| Agenus | 156.31M |
| Fennec Pharmaceuticals | 21.25M |
| Adlai Nortye | 5.00M |
BVS News
- 1 day ago - Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 7 weeks ago - Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 - GlobeNewsWire
- 3 months ago - Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility - GlobeNewsWire
- 3 months ago - Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - GlobeNewsWire
- 4 months ago - BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Business Wire
- 4 months ago - Bioventus Names Robert Claypoole as President and Chief Executive Officer - GlobeNewsWire
- 5 months ago - Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis - GlobeNewsWire